JPH09508411A - クラブラン酸の塩の製法 - Google Patents
クラブラン酸の塩の製法Info
- Publication number
- JPH09508411A JPH09508411A JP7520445A JP52044595A JPH09508411A JP H09508411 A JPH09508411 A JP H09508411A JP 7520445 A JP7520445 A JP 7520445A JP 52044595 A JP52044595 A JP 52044595A JP H09508411 A JPH09508411 A JP H09508411A
- Authority
- JP
- Japan
- Prior art keywords
- clavulanic acid
- solution
- salt
- water
- organic solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical class OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 title claims abstract description 128
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims abstract description 129
- 229960003324 clavulanic acid Drugs 0.000 claims abstract description 115
- 238000000034 method Methods 0.000 claims abstract description 101
- 150000003839 salts Chemical class 0.000 claims abstract description 93
- 239000003960 organic solvent Substances 0.000 claims abstract description 53
- 239000008346 aqueous phase Substances 0.000 claims abstract description 42
- 239000002243 precursor Substances 0.000 claims abstract description 38
- 150000001875 compounds Chemical class 0.000 claims abstract description 30
- 238000000926 separation method Methods 0.000 claims abstract description 25
- 239000007787 solid Substances 0.000 claims abstract description 10
- 238000012545 processing Methods 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 76
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 59
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical group [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 claims description 44
- 238000002156 mixing Methods 0.000 claims description 25
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 23
- 239000007864 aqueous solution Substances 0.000 claims description 21
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical group CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 17
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 17
- 239000012071 phase Substances 0.000 claims description 17
- 239000012074 organic phase Substances 0.000 claims description 16
- -1 clavulanate ions Chemical class 0.000 claims description 15
- ZUFQCVZBBNZMKD-UHFFFAOYSA-M potassium 2-ethylhexanoate Chemical compound [K+].CCCCC(CC)C([O-])=O ZUFQCVZBBNZMKD-UHFFFAOYSA-M 0.000 claims description 15
- 229940090805 clavulanate Drugs 0.000 claims description 14
- 150000001450 anions Chemical class 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000013078 crystal Substances 0.000 claims description 8
- 238000002955 isolation Methods 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical group CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 239000012736 aqueous medium Substances 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 150000001768 cations Chemical class 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 3
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 3
- 235000019797 dipotassium phosphate Nutrition 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 235000010216 calcium carbonate Nutrition 0.000 claims description 2
- 150000001735 carboxylic acids Chemical class 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 229940086066 potassium hydrogencarbonate Drugs 0.000 claims description 2
- 229940083542 sodium Drugs 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- SLFUXNFVAANERW-UHFFFAOYSA-N ethyl hexanoate;potassium Chemical compound [K].CCCCCC(=O)OCC SLFUXNFVAANERW-UHFFFAOYSA-N 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 239000008400 supply water Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 20
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 14
- 150000001412 amines Chemical class 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 239000012530 fluid Substances 0.000 description 9
- 239000012535 impurity Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229910052783 alkali metal Inorganic materials 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000000638 solvent extraction Methods 0.000 description 4
- OBETXYAYXDNJHR-UHFFFAOYSA-N 2-Ethylhexanoic acid Chemical compound CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 3
- LAIUFBWHERIJIH-UHFFFAOYSA-N 3-Methylheptane Chemical compound CCCCC(C)CC LAIUFBWHERIJIH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000003781 beta lactamase inhibitor Substances 0.000 description 2
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- MFIGJRRHGZYPDD-UHFFFAOYSA-N n,n'-di(propan-2-yl)ethane-1,2-diamine Chemical compound CC(C)NCCNC(C)C MFIGJRRHGZYPDD-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 description 2
- OBETXYAYXDNJHR-SSDOTTSWSA-M (2r)-2-ethylhexanoate Chemical compound CCCC[C@@H](CC)C([O-])=O OBETXYAYXDNJHR-SSDOTTSWSA-M 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 241000187433 Streptomyces clavuligerus Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- RXROCZREIWVERD-UHFFFAOYSA-L cadmium(2+);2-ethylhexanoate Chemical compound [Cd+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O RXROCZREIWVERD-UHFFFAOYSA-L 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- 150000004684 trihydrates Chemical group 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D503/00—Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Cephalosporin Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.クラブラン酸の塩の製法であって、クラブラン酸またはその不安定な誘導 体の完全にまたは部分的に水不混和性有機溶媒中の溶液を、高乱流および/また は剪断圧の領域である接触領域にて、溶液または懸濁液のカウンターアニオンと のカチオンを形成する塩の塩先駆体化合物と接触させ、該カウンターアニオンが 水の存在下でクラブラン酸塩のアニオンと交換能を有し、それでクラブラン酸の 塩の水相中溶液が形成され、ついで有機溶媒および水相を分離工程、つづいてさ らなる加工処理工程の間に物理的に分離し、クラブラン酸の塩を固体として溶液 より単離することを特徴とする方法。 2.塩がクラブラン酸カリウムである請求項1記載の方法。 3.有機溶媒が、n−ブタノール、酢酸エチル、酢酸n−ブチル、および一般 式:R1COR2(R1およびR2は独立してC1-10アルキル基である)のケトンか ら選択される前記した請求項のいずれか1つに記載の方法。 4.有機溶媒がメチルイソブチルケトンである請求項3記載の方法。 5.クラブラン酸溶液の濃度が、クラブラン酸にて約500ないし20,00 0μg/ml(0.0025Mないし0.1M)である前記した請求項のいずれか 1つに記載の方法。 6.塩先駆体化合物のカウンターアニオンが、水素カルボネート、カルボネー ト、水素ホスフェート、および式:R−CO2H(RはC1-20アルキルである) の弱い有機カルボン酸のアニオンから選択される前記した請求項のいずれか1つ に記載の方法。 7.塩先駆体化合物が炭酸水素ナトリウムまたはカリウム、リン酸水素カリウ ム、炭酸カルシウム、および2−エチルヘキサン酸カリウムから選択される請求 項6記載の方法。 8.塩先駆体化合物を、その先駆体化合物を溶媒に溶かすかまたは懸濁させ、 2種の溶液または溶液と懸濁液を混合することによりクラブラン酸の溶液と接触 させる前記した請求項のいずれか1つに記載の方法。 9.2−エチルヘキサン酸カリウムが塩先駆体であり、2−エチルヘキサン酸 カリウムにて0.5ないし5.0Mの溶液濃度で、有機溶媒の溶液にて用いる請求 項8記載の方法。 10.塩先駆体化合物を溶解した有機溶媒含有の水に溶かすかまたは懸濁させ、 その物をクラブラン酸の溶液と接触させることにより、水を接触領域にて供給す る前記した請求項のいずれか1つに記載の方法。 11.溶解または懸濁した水を含有するクラブラン酸の溶液により、水を接触領 域にて供給する請求項1ないし10のいずれか1つに記載の方法。 12.塩先駆体化合物を有機溶媒に溶かすかまたは懸濁させることにより水を接 触領域にて供給し、該溶媒が溶解または懸濁した水を含有する前記した請求項の いずれか1つに記載の方法。 13.メチルイソブチルケトンをクラブラン酸および先駆体に関する有機溶媒と して用い、0.1ないし7.5%v:vの溶解した水を含有する請求項12記載の 方法。 14.水または水性媒体を、クラブラン酸溶液および塩先駆体の有機溶媒中溶液 または懸濁液に添加することにより水を接触領域にて供給し、それらの物質が接 触領域にて接触するようにする前記した請求項のいずれか1つに記載の方法。 15.実施条件が、とりわけ、できる限り、クラブラン酸が有機溶媒の溶液から その塩の溶液としての水相に抽出され、クラブラン酸の塩の水相中濃縮溶液が形 成されるように選択される前記した請求項のいずれか1つに記載の方法。 16.クラブラン酸の塩がクラブラン酸カリウムであり、水相中のクラブラン酸 カリウムの濃度が約10〜40重量%(約0.4〜1.7M)である請求項15記 載の方法。 17.接触領域における水:有機溶媒の体積比率が、1:50ないし1:300 の範囲にある前記した請求項のいずれか1つに記載の方法。 18.成分間の接触が、1個またはそれ以上の乱流形成エレメントがパイプライ ン内に配置され、その間を成分が流れる型のイン・ライン式ミキサー、あるいは 実質的に円形の断面であって、少なくとも1個の接線方向の引入口と1個の軸方 向の流出口を有するチャンバーからなる型の渦式チャンバー、または激しい乱流 および/または剪断圧がタービンもしくはプロペラにより形成される窪みのある ホモジナイザーを用いて達成される前記した請求項のいずれか1つに記載の方法 。 19.生成されるクラブラン酸塩がクラブラン酸カリウムであり、塩先駆体がメ チルイソブチルケトンの溶液の2−エチルヘキサン酸カリウムであって、水を混 合領域に添加し、クラブラン酸溶液:2−エチルヘキサン酸カリウム溶液:混合 装置に導入される水の相対的体積比が約180±25:2±0.2:1±0.2で ある前記した請求項のいずれか1つに記載の方法。 20.有機相と水相の接触している時間の合計が1時間またはそれより少ない時 間である前記した請求項のいずれか1つに記載の方法。 21.調製されるクラブラン酸の塩がクラブラン酸カリウムであり、クラブラン 酸カリウムが1時間またはそれより少ない時間水相中に滞留している請求項20 記載の方法。 22.有機相と水相が接触している間に、75%より多いクラブラン酸塩のイオ ンが有機相より移動している前記した請求項のいずれか1つに記載の方法。 23.残りのクラブラン酸の溶液を含有する消費された有機溶媒相の流出物を、 もう一度および所望によりその後、2または3以上の段階にて、請求項1に記載 の方法の混合および分離段階に付し、さらなる割合のクラブラン酸を塩として抽 出する前記した請求項のいずれか1つに記載の方法。 24.そのような2段階方法にて、クラブラン酸の塩の水溶液と、未反応の残り の塩先駆体化合物とからなる、第2段階の分離工程の水相流出物を、水性媒体源 として、該方法の第1段階の接触領域にフィードバックする請求項23記載の方 法。 25.塩先駆体化合物と付加的な水を第2段階の接触領域に導入する請求項24 記載の方法。 26.分離段階から流出物として得たクラブラン酸の塩の水溶液を有機溶媒と混 合し、所望により冷却してもよく、溶液より塩を結晶として沈殿させる前記した 請求項のいずれか1つに記載の方法。 27.クラブラン酸の塩がクラブラン酸カリウムであり、氷溶液と混合する有機 溶媒がイソプロピルアルコールである請求項26記載の方法。 28.請求項1〜27のいずれか1つに記載の方法により生成されるクラブラン 酸カリウム。 29.請求項28に記載のクラブラン酸カリウムからなる細菌感染症の治療用医 薬処方。 30.細菌感染症の治療に用いるための医薬処方の製造における請求項28に記 載のクラブラン酸カリウムの使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9401969A GB9401969D0 (en) | 1994-02-02 | 1994-02-02 | Process |
| GB9401969.2 | 1994-02-02 | ||
| PCT/GB1995/000191 WO1995021173A1 (en) | 1994-02-02 | 1995-01-31 | Process for the preparation of a salt of clavulanic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH09508411A true JPH09508411A (ja) | 1997-08-26 |
| JP4074336B2 JP4074336B2 (ja) | 2008-04-09 |
Family
ID=10749727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP52044595A Expired - Fee Related JP4074336B2 (ja) | 1994-02-02 | 1995-01-31 | クラブラン酸の塩の製法 |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US5965728A (ja) |
| EP (1) | EP0741732B1 (ja) |
| JP (1) | JP4074336B2 (ja) |
| KR (1) | KR100388769B1 (ja) |
| CN (1) | CN1065246C (ja) |
| AP (1) | AP610A (ja) |
| AT (1) | ATE202358T1 (ja) |
| AU (1) | AU688849B2 (ja) |
| BG (1) | BG63307B1 (ja) |
| BR (1) | BR9506919A (ja) |
| CA (1) | CA2182504C (ja) |
| CZ (1) | CZ294005B6 (ja) |
| DE (1) | DE69521415T2 (ja) |
| DK (1) | DK0741732T3 (ja) |
| ES (1) | ES2159626T3 (ja) |
| FI (1) | FI111949B (ja) |
| GB (1) | GB9401969D0 (ja) |
| GR (1) | GR3036602T3 (ja) |
| HU (1) | HU226597B1 (ja) |
| MX (1) | MX9603204A (ja) |
| NO (1) | NO314505B1 (ja) |
| NZ (1) | NZ278927A (ja) |
| OA (1) | OA10587A (ja) |
| PL (1) | PL181451B1 (ja) |
| PT (1) | PT741732E (ja) |
| RO (1) | RO115730B1 (ja) |
| RU (1) | RU2140418C1 (ja) |
| SI (1) | SI0741732T1 (ja) |
| SK (1) | SK282544B6 (ja) |
| UA (1) | UA48944C2 (ja) |
| WO (1) | WO1995021173A1 (ja) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT400033B (de) | 1992-03-10 | 1995-09-25 | Biochemie Gmbh | Neues verfahren zur isolierung und reinigung von clavulansäure und zur herstellung von pharmakologisch verträglichen salzen derselben |
| SI9400107A (en) | 1994-03-02 | 1995-10-31 | Lek Tovarna Farmacevtskih | New process of the isolation of clavulanic acid and its pharmaceutical salts from fermented broth of streptomyces sp.p 6621 ferm p 2804. |
| GB9500977D0 (en) * | 1995-01-19 | 1995-03-08 | Smithkline Beecham Plc | Novel process |
| SI9500134B (sl) * | 1995-04-20 | 2004-04-30 | Lek, | Postopek za pripravo čistih alkalijskih soli klavulanske kisline |
| GB9515809D0 (en) * | 1995-08-02 | 1995-10-04 | Smithkline Beecham Plc | Process |
| AT403375B (de) * | 1995-11-15 | 1998-01-26 | Biochemie Gmbh | Verfahren zur fällung von alkalisalzen der clavulansäure |
| ZA975198B (en) * | 1996-06-13 | 1997-12-15 | Smithkline Beecham Corp | Improved process for preparing potassium clavulanate. |
| WO1998042858A1 (en) * | 1997-03-24 | 1998-10-01 | Cipan-Companhia Industrial Produtora De Antibióticos, S.A. | Process for the isolation of a pharmaceutically acceptable alkali metal salt of clavulanic acid |
| PT867515E (pt) | 1997-03-24 | 2000-05-31 | Cipan Companhia Ind P De Antib | Processo para isolar um sal de acido clavulanico e de um metal alcalino farmaceuticamente aceitavel |
| DZ2456A1 (fr) * | 1997-04-04 | 2003-01-18 | Smithkline Beecham Plc | Procédé de préparation de sels de l'acide clavulanique. |
| KR100892864B1 (ko) | 2001-08-02 | 2009-04-15 | 주식회사 엘지생명과학 | 4-아미노메틸렌-피롤리딘-3-온의 아미노-보호 유도체및/또는 4-아미노메틸렌-피롤리딘-3-알콕시이미노유도체들 및/또는 제미플록사신 또는 그것의 염의 제조를위한 공정 |
| AU2017295866A1 (en) | 2016-07-14 | 2019-01-17 | Achaogen, Inc. | Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections |
| CN108822134B (zh) * | 2018-04-25 | 2021-06-25 | 国药集团威奇达药业有限公司 | 克拉维酸叔丁胺盐的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1508977A (en) * | 1974-04-20 | 1978-04-26 | Beecham Group Ltd | Beta-lactam antibiotic from streptomyces clavuligerus |
| ES444195A1 (es) * | 1974-10-09 | 1977-08-01 | Beecham Group Ltd | Un procedimiento para la preparacion de acido clavulanico. |
| GB1543563A (en) * | 1975-02-07 | 1979-04-04 | Glaxo Lab Ltd | Beta-lactam antibiotic in purified form |
| GB1563103A (en) * | 1975-10-13 | 1980-03-19 | Beecham Group Ltd | Process for the preparation of clavulanic acid |
| GB1578739A (en) * | 1976-07-23 | 1980-11-05 | Beecham Group Ltd | Amine salts of clavulanic acid methods for their preparation and compositions containing them |
| DE3063683D1 (en) * | 1979-08-24 | 1983-07-14 | Beecham Group Plc | Amine salt of clavulanic acid, its preparation and use |
| GB8404749D0 (en) * | 1984-02-23 | 1984-03-28 | Atomic Energy Authority Uk | Fluidic contactor |
| ES2010143A6 (es) * | 1989-03-01 | 1989-10-16 | Pharma Mar S A Pharmar | Un nuevo procedimiento de obtencion del acido z(2r,5r)-3-(2-hiadroxietiliden)-7- oxo-4-oxa-1-azabiciclo(3,2,0) -heptano-2-carboxilico y de sales estares farmaceutiacamente aceptables del mismo,a partir de caldos de fermentacion de streptomyces, sp. |
-
1994
- 1994-02-02 GB GB9401969A patent/GB9401969D0/en active Pending
-
1995
- 1995-01-31 HU HU9602128A patent/HU226597B1/hu not_active IP Right Cessation
- 1995-01-31 NZ NZ278927A patent/NZ278927A/en not_active IP Right Cessation
- 1995-01-31 CZ CZ19962294A patent/CZ294005B6/cs not_active IP Right Cessation
- 1995-01-31 JP JP52044595A patent/JP4074336B2/ja not_active Expired - Fee Related
- 1995-01-31 PT PT95907075T patent/PT741732E/pt unknown
- 1995-01-31 RO RO96-01582A patent/RO115730B1/ro unknown
- 1995-01-31 DE DE69521415T patent/DE69521415T2/de not_active Expired - Lifetime
- 1995-01-31 SK SK1003-96A patent/SK282544B6/sk not_active IP Right Cessation
- 1995-01-31 CN CN95192179A patent/CN1065246C/zh not_active Expired - Fee Related
- 1995-01-31 PL PL95315782A patent/PL181451B1/pl not_active IP Right Cessation
- 1995-01-31 RU RU96117347A patent/RU2140418C1/ru not_active IP Right Cessation
- 1995-01-31 EP EP95907075A patent/EP0741732B1/en not_active Expired - Lifetime
- 1995-01-31 SI SI9530525T patent/SI0741732T1/xx unknown
- 1995-01-31 BR BR9506919A patent/BR9506919A/pt not_active Application Discontinuation
- 1995-01-31 CA CA002182504A patent/CA2182504C/en not_active Expired - Fee Related
- 1995-01-31 MX MX9603204A patent/MX9603204A/es not_active IP Right Cessation
- 1995-01-31 DK DK95907075T patent/DK0741732T3/da active
- 1995-01-31 AP APAP/P/1996/000838A patent/AP610A/en active
- 1995-01-31 AU AU15412/95A patent/AU688849B2/en not_active Ceased
- 1995-01-31 US US08/663,158 patent/US5965728A/en not_active Expired - Lifetime
- 1995-01-31 WO PCT/GB1995/000191 patent/WO1995021173A1/en not_active Ceased
- 1995-01-31 AT AT95907075T patent/ATE202358T1/de not_active IP Right Cessation
- 1995-01-31 KR KR1019960704202A patent/KR100388769B1/ko not_active Expired - Fee Related
- 1995-01-31 ES ES95907075T patent/ES2159626T3/es not_active Expired - Lifetime
- 1995-01-31 UA UA96083392A patent/UA48944C2/uk unknown
-
1996
- 1996-08-01 NO NO19963217A patent/NO314505B1/no not_active IP Right Cessation
- 1996-08-01 FI FI963050A patent/FI111949B/fi active
- 1996-08-01 BG BG100765A patent/BG63307B1/bg unknown
- 1996-08-02 OA OA60872A patent/OA10587A/en unknown
-
2001
- 2001-09-12 GR GR20010401463T patent/GR3036602T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5184465B2 (ja) | クラブラン酸カリウムの製造方法 | |
| JPH09508411A (ja) | クラブラン酸の塩の製法 | |
| JP4111998B2 (ja) | クラブラン酸抽出法 | |
| JP2003533529A (ja) | クラブラン酸塩の精製方法 | |
| HK1012373B (en) | Process for the preparation of a salt of clavulanic acid | |
| AU706196C (en) | Clavulanic acid extraction process | |
| HK1036621A (en) | Process for the preparation of potassium clavulanate | |
| HK1004134B (en) | Clavulanic acid extraction process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050927 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051222 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060213 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060327 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070529 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070829 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071005 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070927 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071105 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071029 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080108 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080125 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110201 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120201 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130201 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130201 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140201 Year of fee payment: 6 |
|
| LAPS | Cancellation because of no payment of annual fees |